Skip to main content

Advertisement

Table 4 Clinical Outcome of study patients during in-hospital and 30-day follow-up based on MAGE levels

From: Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions

MAGE (mmol/L)   <2.37 2.37-3.65 >3.65 P
Subject number (n) 237 80 78 79 NA
Composite MACE 35 (14.8) 6 (7.5) 11 (14.1) 18 (22.8) 0.025
Cardiac death 4 (1.7) 1 (1.3) 1 (1.3) 2 (2.5) 0.775
Reinfarction 3 (1.3) 0 (0) 1 (1.3) 2 (2.5) 0.361
Repeated TVR 3 (1.3) 0 (0) 1 (1.3) 2 (2.5) 0.361
Recurrent angina 15 (6.3) 3 (3.8) 5 (6.4) 7 (8.9) 0.416
Malignant arrhythmia 10 (4.2) 2 (2.5) 3 (3.8) 5 (6.3) 0.477
Non-cardiac death 1 (0.4) 0 (0) 1 (1.3) 0 (0) 0.359
Non-IRA revascularization 53 (22.4) 12 (15) 16 (21) 25 (32) 0.037
  1. Data given as mean ± SD or n (%).
  2. MAGE, the mean amplitude of glycemic excursions; MACE, major adverse cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.